Cancer

Long-term cardiomyopathy risk varies by chemo agent

(HealthDay)—Long-term cardiomyopathy risk varies by chemotherapy agent for childhood cancer survivors, with a decreased risk for daunorubicin versus doxorubicin, according to a study recently published in JAMA Oncology.

page 1 from 12